Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EBT: 2021-2025

Historic EBT for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $48.0 million.

  • Krystal Biotech's EBT rose 61.13% to $48.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $186.9 million, marking a year-over-year increase of 225.68%. This contributed to the annual value of $95.4 million for FY2024, which is 639.37% up from last year.
  • Latest data reveals that Krystal Biotech reported EBT of $48.0 million as of Q3 2025, which was up 2.55% from $46.8 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's EBT peaked at $80.7 million during Q3 2023, and registered a low of -$50.0 million during Q1 2022.
  • Its 3-year average for EBT is $21.3 million, with a median of $29.8 million in 2024.
  • As far as peak fluctuations go, Krystal Biotech's EBT slumped by 215.99% in 2022, and later surged by 4,577.79% in 2025.
  • Over the past 5 years, Krystal Biotech's EBT (Quarterly) stood at -$21.8 million in 2021, then tumbled by 46.99% to -$32.1 million in 2022, then skyrocketed by 133.25% to $10.7 million in 2023, then skyrocketed by 356.13% to $48.6 million in 2024, then skyrocketed by 61.13% to $48.0 million in 2025.
  • Its last three reported values are $48.0 million in Q3 2025, $46.8 million for Q2 2025, and $43.6 million during Q1 2025.